Singapore, May 26 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durv... Read More
Singapore, May 26 -- The Health Sciences Authority received information related to the study titled 'TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-labe... Read More
Singapore, May 26 -- The Health Sciences Authority received information related to the study titled 'A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety... Read More
Singapore, May 26 -- The Health Sciences Authority received information related to the study titled 'N-Acetylcysteine or Erdosteine for Exacerbations of Chronic Obstructive Pulmonary Disease (NEX COPD... Read More
Singapore, May 26 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembro... Read More
Singapore, May 26 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evalu... Read More
Singapore, May 26 -- The Health Sciences Authority received information related to the study titled 'Responses Against Paramyxoviruses in T cells with crOss Reactivity'. The following are the other re... Read More
Singapore, May 26 -- The Health Sciences Authority received information related to the study titled 'Effect of innate immune reprogramming by primary dengue on host response to secondary dengue'. The ... Read More
Singapore, May 26 -- The Health Sciences Authority received information related to the study titled 'Validation of Gore Test in patients with Sphincteric Dyssynergia presenting with Dysfunctional Void... Read More
Singapore, May 26 -- The Health Sciences Authority received information related to the study titled 'An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembr... Read More